J. R. Gray

901 total citations
30 papers, 687 citations indexed

About

J. R. Gray is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J. R. Gray has authored 30 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Surgery. Recurrent topics in J. R. Gray's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). J. R. Gray is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). J. R. Gray collaborates with scholars based in United States, Canada and United Kingdom. J. R. Gray's co-authors include John D. Hainsworth, F. Anthony Greco, Linda Rabeneck, Walter C. MacDonald, Andrew J. Coldman, Steven L. Stroup, John T. Scales, Elaine Lai‐Han Leung, Bruce Morland and Tim Hassall and has published in prestigious journals such as Journal of Clinical Oncology, Nature Neuroscience and Cancer.

In The Last Decade

J. R. Gray

28 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. R. Gray United States	12	331	269	199	157	143	30	687
Polymnia Galiatsatos Canada	9	309 0.9×	241 0.9×	104 0.5×	179 1.1×	99 0.7×	16	815
Swati Garg Canada	14	235 0.7×	128 0.5×	102 0.5×	81 0.5×	287 2.0×	47	788
Haiping Zhang China	15	203 0.6×	77 0.3×	237 1.2×	167 1.1×	78 0.5×	58	697
Shu Hirai Japan	14	133 0.4×	136 0.5×	155 0.8×	349 2.2×	157 1.1×	50	694
Vibha Dutta India	13	143 0.4×	154 0.6×	78 0.4×	129 0.8×	55 0.4×	47	557
G. Di Febo Italy	19	90 0.3×	216 0.8×	80 0.4×	387 2.5×	113 0.8×	41	973
J. Margery France	15	239 0.7×	66 0.2×	347 1.7×	83 0.5×	75 0.5×	104	670
Cuicui Xiao China	11	133 0.4×	98 0.4×	95 0.5×	79 0.5×	277 1.9×	32	781
Edythe A. Albano United States	13	202 0.6×	128 0.5×	114 0.6×	76 0.5×	74 0.5×	24	714
Douglas P. Rhone United States	14	71 0.2×	85 0.3×	72 0.4×	48 0.3×	76 0.5×	25	441

Countries citing papers authored by J. R. Gray

Since Specialization

Citations

This map shows the geographic impact of J. R. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. R. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. R. Gray more than expected).

Fields of papers citing papers by J. R. Gray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. R. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. R. Gray. The network helps show where J. R. Gray may publish in the future.

Co-authorship network of co-authors of J. R. Gray

This figure shows the co-authorship network connecting the top 25 collaborators of J. R. Gray. A scholar is included among the top collaborators of J. R. Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. R. Gray. J. R. Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeCastro, G. Joel, Mark N. Stein, Cory Abate‐Shen, et al.. (2024). 1974P A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder. Annals of Oncology. 35. S1143–S1143. 2 indexed citations

Gray, J. R., Elaine Lai‐Han Leung, & John T. Scales. (2009). Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Alimentary Pharmacology & Therapeutics. 29(10). 1114–1120. 45 indexed citations

Gray, J. R., et al.. (2009). Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in British Columbia. Alimentary Pharmacology & Therapeutics. 29(8). 882–891. 7 indexed citations

Sequist, Lecia V., Scott Gettinger, Ronald B. Natale, et al.. (2009). A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. Journal of Clinical Oncology. 27(15_suppl). 8073–8073. 11 indexed citations

Begum, Gulnaz, Mark Cook, Sarah Lawson, et al.. (2006). Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation. Bone Marrow Transplantation. 37(4). 419–423. 9 indexed citations

Murphy, Patrick B., John D. Hainsworth, David R. Spigel, et al.. (2006). Topotecan—Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 24(18_suppl). 17000–17000. 3 indexed citations

Gray, J. R., John D. Hainsworth, Anthony A. Meluch, et al.. (2005). Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network trial. Journal of Clinical Oncology. 23(16_suppl). 4018–4018. 7 indexed citations

Medhurst, Andrew D., B.‐Y. Zeng, Charles Kornreich, et al.. (2001). Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment. Neuroscience. 105(2). 353–364. 8 indexed citations

Greco, F. Anthony, Joan B. Erland, Lisa H. Morrissey, et al.. (2000). Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Annals of Oncology. 11(2). 211–215. 80 indexed citations

10.

Hainsworth, John D., J. R. Gray, Howard A. Burris, & F. Anthony Greco. (2000). Paclitaxel, carboplatin and topotecan as initial therapy for small cell lung cancer. Lung Cancer. 29(1). 40–40. 3 indexed citations

11.

Meluch, Anthony A., John D. Hainsworth, J. R. Gray, et al.. (1999). Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.. PubMed. 5(2). 84–91. 40 indexed citations

12.

Gray, J. R.. (1998). The tumor conference: an integral component of the oncology program.. PubMed. 6(1). 10–4. 4 indexed citations

13.

Hainsworth, John D., J. R. Gray, Steven L. Stroup, et al.. (1997). Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.. Journal of Clinical Oncology. 15(12). 3464–3470. 70 indexed citations

14.

Hainsworth, John D., et al.. (1997). 17 Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): A report on 117 patients (PTS) treated by the Minnie Pearl cancer research network. Lung Cancer. 18. 7–7. 3 indexed citations

15.

Greco, F. Anthony, Steven L. Stroup, J. R. Gray, & John D. Hainsworth. (1996). Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.. Journal of Clinical Oncology. 14(5). 1642–1648. 27 indexed citations

16.

Johnson, Bruce E., J. R. Gray, R. Ilona Linnoila, et al.. (1996). Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.. Journal of Clinical Oncology. 14(3). 806–813. 97 indexed citations

17.

Gray, J. R., Andrew J. Coldman, & Walter C. MacDonald. (1992). Cigarette and alcohol use in patients with adenocarcinoma of the gastric cardia or lower esophagus. Cancer. 69(9). 2227–2231. 60 indexed citations

18.

Gray, J. R., et al.. (1990). Applying a PC accelerator board for medical imaging. IEEE Engineering in Medicine and Biology Magazine. 9(3). 61–63.

19.

Gray, J. R., Ahmad M. Khalil, & Jerilynn C. Prior. (1989). Acute arsenic toxicity--an opaque poison.. PubMed. 40(4). 226–7. 9 indexed citations

20.

Gray, J. R. & Linda Rabeneck. (1989). Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients.. PubMed. 84(12). 1521–4. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact